Oral oncology · 2025
Oncological outcomes of pathological extranodal extension (pENE) in oral squamous cell carcinoma (OSCC): A proposal to refine the current staging.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nemade Hemant, Thaduri Abhinav, Gondi Jonathan T, Chava Sravan Kumar, Kumar Anil, Arya Sahithi Shilpa, Sekara Rao S L M Chandra
Аннотация
BACKGROUND: Extranodal extension (ENE) is an important prognostic factor in oral squamous cell carcinoma (OSCC), often associated with poor survival outcomes. However, the current nodal (N) staging system may need to be revised to reflect the prognosis. Emerging evidence suggests that the number of positive lymph nodes may offer improved prognostic accuracy. This study evaluates the outcomes of OSCC patients with pathological ENE (pENE) and explores the prognostic significance of absolute positive lymph node count.
MATERIALS AND METHODS: This retrospective cohort study analyzed 640 OSCC patients with pENE who underwent curative-intent surgery and standard adjuvant therapies between May 2015 and December 2021. Receiver Operating Characteristic (ROC) curve analysis was performed to identify a cutoff for the number of positive lymph nodes predicting overall survival (OS). Survival analyses were conducted using Kaplan-Meier curves, and Cox proportional hazards regression was used to identify independent predictors of OS and disease-free survival (DFS).
RESULTS: In the entire cohort, the median DFS was 16 months (95 % CI: 12-19), and the mean OS was 57 months (95 % CI: 52-62). ROC analysis identified four positive lymph nodes as the optimal cutoff for predicting OS (AUC = 0.562, p = 0.01), with a sensitivity of 46.3 % and specificity of 65.2 %. Patients with > 4 positive lymph nodes had significantly poorer outcomes compared to those with ≤ 4 nodes: median DFS was 9 months vs. 21 months (p < 0.001), and mean OS was 26 months vs. 61 months (p < 0.001). Multivariate Cox regression confirmed the number of positive lymph nodes as an independent predictor for OS (HR = 0.6, p < 0.001) and DFS (HR = 0.5, p < 0.001).
CONCLUSION: Patients with pENE and > four positive lymph nodes have significantly worse survival outcomes despite standard adjuvant therapies. This highlights the need for improved risk stratification in the current nodal staging system. These findings suggest incorporating lymph node burden into staging frameworks could improve prognostic accuracy.
MATERIALS AND METHODS: This retrospective cohort study analyzed 640 OSCC patients with pENE who underwent curative-intent surgery and standard adjuvant therapies between May 2015 and December 2021. Receiver Operating Characteristic (ROC) curve analysis was performed to identify a cutoff for the number of positive lymph nodes predicting overall survival (OS). Survival analyses were conducted using Kaplan-Meier curves, and Cox proportional hazards regression was used to identify independent predictors of OS and disease-free survival (DFS).
RESULTS: In the entire cohort, the median DFS was 16 months (95 % CI: 12-19), and the mean OS was 57 months (95 % CI: 52-62). ROC analysis identified four positive lymph nodes as the optimal cutoff for predicting OS (AUC = 0.562, p = 0.01), with a sensitivity of 46.3 % and specificity of 65.2 %. Patients with > 4 positive lymph nodes had significantly poorer outcomes compared to those with ≤ 4 nodes: median DFS was 9 months vs. 21 months (p < 0.001), and mean OS was 26 months vs. 61 months (p < 0.001). Multivariate Cox regression confirmed the number of positive lymph nodes as an independent predictor for OS (HR = 0.6, p < 0.001) and DFS (HR = 0.5, p < 0.001).
CONCLUSION: Patients with pENE and > four positive lymph nodes have significantly worse survival outcomes despite standard adjuvant therapies. This highlights the need for improved risk stratification in the current nodal staging system. These findings suggest incorporating lymph node burden into staging frameworks could improve prognostic accuracy.